PsygaBio

PsygaBio is a biotechnology startup based in Israel founded in 2021. The company's mission is to unleash the full potential of psychedelic mushrooms for therapeutic purposes. Led by renowned researcher Prof. Dedi Meiri from the Technion – Israel Institute of Technology, PsygaBio is focused on developing groundbreaking therapeutics derived from natural compounds. The company is supported by robust scientific capabilities and is utilizing Cannasoul’s proprietary analytical platform, data-driven approach, unique knowhow, and a clinical trial framework to identify and develop active compounds from mushrooms.

PsygaBio's expertise encompasses the entire process from cultivation and extraction of mushrooms to the development of clinically approved formulations. With a focus on drug discovery and the potential applications of psychedelics in the field of health care, the company presents an innovative approach to harnessing the medicinal properties of natural compounds.

As of now, there is no information available about the company's last investment or the involved investors. However, given the increasing interest in biotechnology and the potential of psychedelic compounds in medicine, PsygaBio may attract significant attention and investment in the future.